ıcknowledgement Number:791686251071122

Date of filing : 07-Nov-20

INDIAN INCOME TAX RETURN ACKNOWLEDGEMENT

[Where the data of the Return of Income in Form ITR-1 (SAHAJ), ITR-2, ITR-3, ITR-4(SUGAM), ITR-5, ITR-6, ITR-7 filed and verified]
(Please see Rule 12 of the Income-tax Rules, 1962)

Assessment Year
2022-23

PAN	AACCD2775Q		
Name	DR NRKBIOTECH PRIVATE LIMITED		
Address	8-2-268/1/A/1/B&C, 2nd Floor , Tulasi Homes , Road No.3 , Banjara Hills S.O , BANJARA HILLS , HYDERABAD , 36-Telangana , 91-India , 500034		
Status	Private Company	Form Number	ITR-6
Filed u/s	139(1) Return filed on or before due date	e-Filing Acknowledgement Number	791686251071122

Taxable Income and Tax details

Current Year business loss, if any	1	18,33,43'
Total Income		(
Book Profit under MAT, where applicable	2	(
Adjusted Total Income under AMT, where applicable	3	(
Net tax payable	4	(
Interest and Fee Payable	5	(
Total tax, interest and Fee payable	6	(
Taxes Paid	7	(
(+)Tax Payable /(-)Refundable (6-7)	8	(
Accreted Income as per section 115TD	9	(
Additional Tax payable u/s 115TD	10	(
Interest payable u/s 115TE	11	(
Additional Tax and interest payable	12	(
Tax and interest paid	13	(
(+)Tax Payable /(-)Refundable (12-13)	14	(

s return has been digitally signed by SOHAM MODI in the capacity of Director having PAN ABMPM6725H from IP address 183.82.4.159
07-Nov-2022

: Sl. No. & Issuer 3097367 & 51172928CN=Capricorn CA 2014,OU=Certifying Authority,O=Capricorn Identity Services Pvt Ltd.,C=IN

System Generated

Barcode/QR Code

AACCD2775Q0679168625107112206FA366C2F38733DF1AA9E54B8F22B30F6CEF46E

DO NOT SEND THIS ACKNOWLEDGEMENT TO CPC, BENGALURU

NAME OF ASSESSEE	: **DR NRKBIOTECH PRIVATE LIMITED**		
PAN	: **AACCD2775Q**		
OFFICE ADDRESS	: 8-2-268/1/A/1/B&C, 2nd Floor, Tulasi Homes, Road No.3 , Banjara Hills S.O, BANJARA HILLS, HYDERABAD, TELANGANA-500034		
STATUS	: PUB NOT INT	ASSESSMENT YEAR	: 2022 - 2023
WARD NO	:	FINANCIAL YEAR	: 2021 - 2022
D.O.I.	: 23/12/2004		
MOBILE NO.	: 8897609209		
EMAIL ADDRESS	: nnagapooja@gmail.com		
NAME OF BANK	: STATE BANK OF INDIA		
MICR CODE	: 62062629504		
IFSC CODE	: SBIN0020458		
ACCOUNT NO.	: 62062629504		
RETURN	: ORIGINAL		
IMPORT DATE	: AIS : 05-11-2022 03:20 PM	TIS : 05-11-2022 03:20 PM	26AS : 05-11-2022 03:19 PM

COMPUTATION OF TOTAL INCOME

PROFITS AND GAINS FROM BUSINESS AND PROFESSION			0
PROFIT BEFORE TAX AS PER PROFIT AND LOSS ACCOUNT		-1695516	
ADD :			
DEPRECIATION DISALLOWED	480044		
DISALLOWED U/S 37	1276	481320	
		-1214196	
LESS : ALLOWED DEPRECIATION		-619241	
		-1833437	

OUT OF LOSS OF RS. 1833437, UNABSORBED DEPRECIATION IS RS. 619241 & BUSINESS LOSS IS RS. 1214196

CURRENT YEAR LOSSES CARRIED FORWARD

BUSINESS LOSS OF Rs. 1214196

UNABSORBED DEPRECIATION OF Rs. 619241

GROSS TOTAL INCOME	NIL
TOTAL INCOME	NIL

COMPUTATION OF TAX ON TOTAL INCOME

TAX ON RS. NIL (AS PER NORMAL PROVISIONS)	NIL

CALCULATION OF BOOK PROFIT U/S 115JB

NET PROFIT AS SHOWN IN THE PROFIT AND LOSS ACCOUNT	1919704
DEDUCT: Reversal of Deferred Tax	-3615220
	-1695516

TAX PAYABLE	NIL

Previous Year Return Filing Details :

Date of Filing	12/03/2022

Information regarding Turnover/Gross Receipt Reported for GST	
GSTR No.	36AACCD2775Q1Z3
Amount of turnover/Gross receipt as per the GST return filed	Nil

FIXED ASSETS

Block	Rate	WDV as on 01/04/2021	Addition		Deduction	Total	Depreciation for the Year	WDV as on 31/03/2022
			More than 180 Days	Less than 180 Days				
		Rs.	Rs.	Rs.	Rs.	Rs.	Rs.	Rs.
BUILDING	10.00%	58,62,635.00	0.00	0.00	0.00	58,62,635.00	5,86,264.00	52,76,371.00
MACHINERY AND PLANT	15.00%	0.00	0.00	4,39,693.00	0.00	4,39,693.00	32,977.00	4,06,716.00
Total		58,62,635.00	0.00	4,39,693.00	0.00	63,02,328.00	6,19,241.00	56,83,087.00

LOSSES TABLE

A.Y.	HEAD	LOSSES		
		BROUGHT FORWARD	SET-OFF	CARRIED FORWARD
2020-21	Ordinary Business	9068419	-	9068419
2021-22	Ordinary Business	4076139	-	4076139
2022-23	Ordinary Business	-	-	1214196
2022-23	Unabsorbed Depreciation	-	-	619241

DISALLOWED U/S 37

Sr. No.	Particulars	Amount
1	GST Late Fee	1018.00
2	Interest on Delay of TDS payment	258.00
	Total	**1276.00**

Drtails of Share holders holding not less than 10% of the voting power at any time during P.Y.

Name	PAN	Percentage of share	Address
NAGA GOVARDHAN KUMAR JANAPATI	AISPJ5862H	50	5-8-50, NEAR RAILWAY A CABIN MENTE VA RI STREET, BHIMAVARAM, WEST GODAVARI TELANGANA - 534201
RAMESH KUMAR RAJU VATSAVAYI	ADDPV8586E	50	
Total		**100.00**	

Schedule-SH1 [SHAREHOLDING OF UNLISTED COMPANY]

1. Details of shareholding at the end of the previous year

Sr. No.	Name of the shareholder	Residential status in India	Type of share	Others	PAN	AADHAAR	Date of allotment	Number of shares held	Face value per share	Issue Price per share	Amount received
1	Naga Goverdhan Kumar J	Resident	Equity Shares		AISPJ5862H		23/12/2004	125000	10	10	1250000
2	V. Ramesh Kumar Raju	Resident	Equity Shares		ADDPV8586E		23/12/2004	125000	10	10	1250000
3	Naga Goverdhan Kumar J	Resident	Preference Shares		AISPJ5862H		23/12/2004	125000	10	10	1250000
4	V. Ramesh Kumar Raju	Resident	Preference Shares		ADDPV8586E		23/12/2004	125000	10	10	1250000
5	Dorjee Tsering Thongdok	Resident	Preference Shares		APPPT6102E		23/12/2004	476000	10	10	4760000
6	Yeshi Dema Thongdok	Resident	Preference Shares		APZPT9360G		23/12/2004	450000	10	10	4500000
7	Kezang Dorjee Thongdok	Resident	Preference Shares		NOABL9999N		23/12/2004	502800	10	10	5028000
	Total							**1928800.00**			**19288000.00**

Schedule-AL1 [Assets and liabilities as at the end of the year]

B. Details of land or building or both not being in the nature of residential house

Sr. No.	Address	Pin code	Date of acquisition	Cost of acquisition	Purpose for which used
1	PLOT NO 11, ADMEASURING 11471 SQ. YARDS, IN SHAPOORJI PALLONJI BIO TECH PARK, PHASE 1, HYDERABAD, RR DIST	500038	2005-04-15	15842501	Own Office
	Total			**15842501**	

Details of Taxpayer Information Summary

S. N.	Information Category (1)	Income Head (2)	Section (3)	Processed Value (4)	Derived Value (5)	As per Computation/ITR (6)	Difference (7)=(5)-(6)	As per 26AS (8)	Difference (9)=(8)-(6)
1	GST turnover	Profit & Loss A/c		0	0	0.00	Nil	0.00	Nil
2	GST purchases	Profit & Loss A/c		5952009	5952009	0.00	5952009.00		

(Managing Director)

INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OFDR. N.R.K. BIOTECH PRIVATE LIMITED

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of**DR. N.R.K.BIO-TECH PRIVATE LIMITED**(the 'Company'), which comprise the Balance Sheet as at 31st March 2022, the Statement of Profit and Lossand the Statement of Cash Flow for the year ended on that date, and notes to financial statements, including a summary of the significant accounting policies and other explanatory information here in after referred to as ("the financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31stMarch, 2022, and its loss, and its cash flows for the year ended on that date.

Basis forOpinion

We conducted our audit of the financial statements in accordance with the Standards on Auditing (SAs) specified under the section 143(10) of theAct. Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of theActand the Rules issued there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for ouropinion on the financial statements.

Information other than the Standalone financial statements and auditor's report thereon:

The Company's Board of Directors are responsible for the other information. The other information comprises the information included in the Director's report but does not include the information in the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit, or otherwise appears to be materially misstated.

If, based on the work we have performed on the other information obtained prior to the date of this auditor's report,we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Other Matter

The financial statements of the company for the year ended 31st March, 2021 were audited by another auditor who expressed unmodified opinion on those statements on 01st November 2021.

Management'sResponsibility for the Financial Statements

The Company's Board of Directors are responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these financial statements that give a true and fair view of the financial position, financial performanceand cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards ("AS") specified under section 133 of the Act read with rule 7 of the Companies (Accounts) Rules,2014. The respective Board of Directors of the company are also responsible for maintenance of the adequate accounting records for safeguarding assets of the company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Board of Directors of the company are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors of the company are responsible for overseeing the financial reporting process of the company.

Auditor's Responsibility for Audit of Financial Statements:

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken based on these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for oneresulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, then we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the entity to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the **"Annexure A"**, a statement on the matters specified in paragraphs 3 and 4 of the Order.

2. As required by Section 143 (3) of the Act,based on our auditwe report that:
   a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit;

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books;

c) The Balance Sheet, the Statement of Profit and Loss, Cash Flow statementdealt with by this Report are in agreement with the books of accounts;

d) In our opinion, the aforesaid financial statements comply with theAccountingstandards ("AS") specified under Section 133 of the Act, read with relevant rules issued there under.

e) On the basis of the written representations received from the directors and taken on record by the Board of Directors, none of the directors is disqualified as on 31stMarch,2022 from being appointed as a director in terms of Section 164 (2) of the Act;

f) With respect to the adequacy of the internal financial controls over financial reporting of the company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure B**". Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the company's internal financial controls over financial reporting.

g) There is no managerial remuneration that is paid to its directors for the year ended 31st March 2022.

h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014 as amended, in our opinion and to the best of our information and according to the explanations given to us:
   i) There company does not have any pending litigations on its financial positions in its financial statements as on 31st March, 2022.
   ii) The Company does not have any long-term contracts, including derivative contracts, for which there were any material foreseeable losses;
   iii) There were no such amounts which were required to be transferred to the Investor Education and Protection Fund during the year ended 31st March 2022.
   iv)
      a. The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other person or entity including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediaries shall, whether, directly or indirectly lend or invest in other person or entity identified in any manner whatsoever ("Ultimate Beneficiaries") by or behalf of the Company or provide any guarantee, security or like on behalf of the Ultimate Beneficiaries;

      b. The management has represented that, to the best of its knowledge and belief, no funds have been received by the company from any person or entity, including foreign entities ("Funding parties"),with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other person or entity identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding parties or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and

c. Based on the audit procedures that were considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (a) and (b) contain any material misstatement.

v) There is no dividend declared or paid during the year by the Company as per the provisions of Section 123 of the Act.

For **Laxminiwas & Co**
Chartered Accountants
Firm Registration Number: 011168S

Vijay Singh
Partner
Membership No. 221671
UDIN: 22221671BCAOOP6733

Place: Hyderabad
Date: 30-09-2022

Annexure A to the Auditors' Report

to the Independent Auditors report on the financial statements of **DR. N.R.K.BIO-TECH PRIVATE LIMITED**for the year ended 31st March 2022

(Referred to the paragraph 1 under Report on other legal and regulatory requirements section of ourreport of even date)

(i). In respect of the company's Property, Plant and Equipment and Intangible Assets:

(a) (A) According to the information and explanations given to us and on the basis of our examination of the records of the company, the company is maintaining proper records showing full particulars including quantitative details and situation of property plant & equipment and there are no intangible assets.

(B)According to the information and explanations given to us and based on our examination of the records of the company, the company does not have intangible assets.

(b) According to the information and explanations given to us, and on the basis of our examination of the records of the company,the company hascarried out physical verification of all its property plant & equipment. In our opinion, the frequency of verification is reasonable considering the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us, the records examined by us, and based on the examination of the conveyance deeds/ registered sale deed provided to us, we report that the title deeds, comprising all the immovable properties of land & building which are free hold, are held in the name of the company as on the balance sheet date.

(d) According to the information and explanations given to us and based on our explanation of the company, the company has not revalued its property, plant, equipment, intangible assets, or both during the year. Therefore, clause 3 (i)(d) of the order does not apply to the company.

(e) According to the information and explanations given to us and based on our examination of the records of the company, there is no proceeding initiated or pending against the company for holding any Benami property under the Prohibition of Benami Property Transactions Act, 1988 and the rules made thereunder. Therefore, Clause 3(i)(e) of the Order does not apply to the company.

(ii). (a) According to the information and explanations given to usand based on our examination of the records of the company, there is noinventory lying with the company as on 31st March, 2022. Therefore, the Clause 3(ii)(a) of the Order is not applicable to the Company.

(b) According to the information and explanations given to us and based on our examination of the records of the company,the company has not been sanctioned with anyworking capital from banks or financial institutions on the basis of security of current assets.Therefore, the Clause 3(ii)(b) of the Order is not applicable to the Company.

(iii). According to the information and explanations given to us and on the basis of our examination of the records of the company, the Company has not made any investments in, provided any guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnerships or any other parties during the year. Accordingly, reporting under clause 3(iii)(a) to (f) are not applicable.

(iv). There are no loans, investments, guarantees and security in respect of which provisions of Sections 185 and Section 186 of the Act are applicable. Accordingly, reporting under clause 3(iii)(iv) are not applicable.

(v). According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not accepted any deposits within the meaning of Sections 73 to 76 of the Act and the Companies (Acceptance of Deposits) Rules, 2014 (as amended). Accordingly, the provisions of Clause 3 (v) of the Order do not apply to the Company.

(vi). According to the information and explanations given to us, maintenance of the cost records as prescribed by the Central Government under section 148(1) of the Actis not applicable to the company. Therefore, the Clause 3 (vi) of the Order is not applicable to the Company.

(vii). According to the information and explanations given to us, in respect of statutory dues:

a) The company has generally been regular in depositing undisputed statutory dues including Provident Fund, Employees' State Insurance, Income tax, Customs duty, Goods and Service Tax, cess and other material statutory dues applicable to it with the appropriate authorities.

   There were no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income Tax, Sales Tax, Service Tax, Goods and Service tax, Customs Duty, cess and other material statutory dues in arrears as at 31st March, 2022 for a period of more than six months from the date they became payable.

b) There are no dues of Income tax, Service tax, customs duty, value added tax, GST and cess which have not been deposited with the appropriate authorities on account of any dispute.

(viii). According to the information and explanations given to us and on the basis of our examination of the records,the Company has not surrendered or disclosed any transaction, previously unrecorded in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year. Accordingly, the requirement to report on clause 3(viii) of the Order is not applicable to the Company.

(ix).

a) According to the information and explanations given to us and on the basis of our examination of the records during the year the Company has not defaulted in repayment of loans or borrowings or in payment of interest thereon to any lender.

b) According to the information and explanations are given to us, the company has not been declared a willful defaulter by any bank or financial institution or any other lenders. Therefore, Clause 3(ix)(b) of the Order does not apply to the Company.

c) According to the information and explanations given to us and based on the examination of records of the company,the company has not raised any term loans from banks and otherfinancial institutions during the year under review. Therefore, the Clause 3 (ix)(c) of the Order is not applicable to the Company.

d) According to the information and explanations given to us and based on the examination of records of the company,no funds raised on a short-term basis have been utilized for long-term purposes.

e) According to the information and explanations given to us and based on the examination of records of the company, the company does not have any subsidiary, associate or joint venture.Therefore, Clause 3 (ix) (e) of the Order does not apply to the Company.

f) According to the information and explanations given to us and based on the examination of records of the company, the company has not raised loans during the year on the pledge of the securities held in its subsidiary. Therefore, Clause 3 (ix) (f) of the Order does not apply to the Company.

(x).

a) According to the information and explanations given to us and based on the examination of records of the company, no money was raised by the way of an initial public offer or further public offer (including debt instruments).

b) According to the information and explanations given to us, the company has not made anypreferential allotment or private placement of shares or convertible debentures (fully, partiallyoptionally convertible) during the year. Accordingly, Clause 3(x)(a) of the Order is notapplicable.

(xi).

a) According to the information and explanations given to us and based on our examination of the records of the Company, based upon the audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to the information and explanations provided by the management, we report that no fraud by the Company or no material fraud on the Company by the officers and employees of the Company has been noticed or reported during the year. Accordingly, Clause 3(xi)(a) of the Order is not applicable.

b) According to the information and explanations given to us and on the basis of our examination of the records during the year, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT – 4 as prescribed under Rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government. Accordingly, the requirement to report on clause 3 (xi) (b)of the Order is not applicable to the Company.

c) According to the information and explanations given to us there are no whistle-blower complaints received by the Company during the year. Accordingly, the provisions stated in paragraph 3(xi)(c) of the Order is not applicable to company.

(xii). According to the information and explanations are given to us and on the basis of our examination of the records of the Company, the Company is not Nidhi Company. Therefore, Clause 3 (xii) (a), (b), and (c) of the Order does not apply to the Company.

(xiii). According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act where applicable and details of such transactions have been disclosed in the financial statements as required by the applicable accounting standards.

(xiv).

a) According to the information and explanations given to us and based on our examination of the records of the company, y, the company is not required to conduct internal audit & hence Clause 3(xiv)(b) of the Order is not applicable.

(xv). According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into any non-cash transactions with directors or persons connected with him. Accordingly, Clause 3(xv) of the Order is not applicable.

(xvi).

a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable to the Company.

b) The Company is not engaged in any Non-Banking Financial or Housing Finance activities. Accordingly, clause 3(xvi)(b) of the Order is not applicable to the Company.

c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable to the Company.

d) According to the information and explanations given to us and on the basis of our examination of the records of the company, the group does not have core investment company.

(xvii). According to the information and explanations given to us and on the basis of our examination of the records of the company, the company has not incurred any cash losses in the financial year and the immediately preceding financial year.

(xviii). According to the information and explanations are given to us, there was resignation of the statutory auditors during the year and we have considered the previous auditor's report for the year ended 31st March 2021 and found that there were no objections, issues or concerns raised by the outgoing auditors.

(xix). According to the information and explanations are given to us and on the basis of our examination of the records of the Company, on the basis of financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, there is no material uncertainty that exists as on the date of the audit report. The Company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date.

(xx). According to the information and explanation provided to us and based on the examination of
records of the company, the company is not subject to compliance requirement with respect to
section 135 of The Companies Act, 2013. Therefore, the Clause 3 (xx) (a) & (b) of the Order is notapplicable to the Company.

(xxi). There are no subsidiaries, associates or joint ventures Accordingly, reporting under clause 3(xxi) of the Order is not applicable.

For Laxminiwas & Co
Chartered Accountants
Firm Registration Number: 011168S

Vijay Singh
Partner
Membership No. 221671
UDIN: 22221671BCAOOP6733

Place: Hyderabad
Date: 30-09-2022

Annexure - B to the Auditors' Report

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

We have audited the internal financial controls over financial reporting of **DR. N.R.K.BIO-TECH PRIVATE LIMITED**("the Company") as of 31st March, 2022, in conjunction with our audit of the financial statements of the Company for the year ended on that date.

Management's Responsibility for Internal Financial Controls

The Board of directors of the company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India ('ICAI'). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and issued by Institute of Chartered accountants of India and the standards on auditing prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that

(1) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;

(2) Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

(3) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Limitations of Internal Financial Controls over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at 31st March, 2022, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Laxminiwas & Co
Chartered Accountants
Firm Registration Number: 011168S

Vijay Singh
Partner
Membership No. 221671
UDIN: 22221671BCAOOP6733

Place: Hyderabad
Date: 30-09-2022

DR. N.R.K. BIO-TECH PRIVATE LIMITED
Balance Sheet as at 31st March 2022
CIN: U45100TG2004PTC044950

Particulars	Sch	As at 31st March,2022	As at 31st March,2021
		₹ In Lakhs	₹ In Lakhs
EQUITY AND LIABILITIES			
SHAREHOLDER'S FUNDS			
(a) Share Capital	3	192.88	192.88
(b) Reserves & Surplus	4	(163.92)	(183.11)
		28.96	**9.77**
Non-current liabilities			
(a) Long-term borrowings	5	32.43	94.17
		32.43	**94.17**
Current Liabilities			
(a) Short Term Borrowings	6	811.65	368.67
(b) Trade payables	7	229.88	-
(c) Other Current Liabilities	8	6.40	34.74
		1,047.92	**403.41**
TOTAL		**1,109.31**	**507.35**
ASSETS			
Non-Current Assets			
(a) Fixed Assets			
(i) Property Plant and Equipment	9	217.63	218.03
(ii) Capital work in progress		699.56	276.22
(b) Non Current Investments	10	-	-
(c) Deferred Tax Asset	11	36.41	0.26
(e) Other non current Investments	12	-	8.50
		953.60	**503.01**
Current Assets			
(d) Cash and cash equivalents	13	16.64	4.34
(e) Short term loans & advances	14	82.46	-
(f) Other current assets	15	56.61	-
		155.71	**4.34**
TOTAL		**1,109.31**	**507.35**

As per our report of even date
For Laxminiwas & Co
Chartered Accountants
Firm's Registration No: 011168S

Vijay Singh
Partner
M. No: 221671

Place : Hyderabad
Date :

For and on Behalf of Directors
DR. N.R.K. BIO-TECH PRIVATE LIMITED
CIN: U45100TG2004PTC044950

Soham Modi
(Director)
DIN: 00522546

B Anand Kumar
(Director)
DIN: 07739186

Dr. N.R.K. Biotech Private Limited HYDERABAD

Company Secretary
ACS:

Place : Hyderabad
Date :

DR. N.R.K. BIO-TECH PRIVATE LIMITED

Statement of Profit and Loss Account for the year ended 31.03.2022

CIN: U45100TG2004PTC044950

Particulars	Sch.	2021-22 ₹ In Lakhs	2020-21 ₹ In Lakhs
INCOME			
Revenue from operations	16	-	-
Other Income	17	-	-
Total Income (I+II)		-	
EXPENDITURE			
Purchases of Stock in Trade	18	-	-
Change in Inventories of finished goods, work in process and stock in trade		-	-
Employee benefits expenses	19	1.56	-
Other Administrative expenses	20	9.95	9.73
Finance cost	21	0.65	24.52
Depreciation and amortization expenses	9	4.80	6.26
Total Expenses		16.96	40.50
Profit before exceptional and extraordinary items and tax (III-IV)		(16.96)	(40.50)
Exceptional items			-
Profit before extraordinary items and tax (V-VI)		-	(40.50)
Extraordinary items		-	-
Profit before tax (VII-VIII)		**(16.96)**	**(40.50)**
Tax expenses			
(1) Current Tax			-
(2) Deferred Tax		(36.15)	7.64
Profit / (Loss) for the period from continuing operations (IX-X)		**19.20**	**(48.14)**
Profit / (Loss) from discontinuing operations			
Tax expense of discontinuing operations		-	-
Profit / (Loss) from Discontinuing Operations (after tax) (XII-XIII)		-	-
Profit / (Loss) for the period (XI-XIV)		**19.20**	**(48.14)**
Earning per equity sahre:			
(1) Basic		7.68	(19.26)
(2) Diluted		7.68	(19.26)

As per our report of even date
For Laxminiwas & Co
Chartered Accountants
Firm's Registration No: 011168S

Vijay Singh
Partner
M. No: 221671

Place : Hyderabad
Date :

For and on Behalf of Directors
DR. N.R.K. BIO-TECH PRIVATE LIMITED
CIN: U45100TG2004PTC044950

Soham Modi
(Director)
DIN: 00522546

B Anand Kumar
(Director)
DIN: 07739186

Company Secretary
ACS:

Place : Hyderabad
Date :

DR. N.R.K. BIO-TECH PRIVATE LIMITED

CASH FLOW STATEMENT

for the year ended 31st March, 2022

Rs in Lakhs

Particulars	Year 2021-22 ₹ in Lakhs		Year 2020-21 ₹ in Lakhs	
A. CASH FLOW FROM OPERATING ACTIVITIES:				
Net Profit / (Loss) Before Tax		19.20		(48.14)
Adjustments for:				
Depreciation	4.80		6.26	
Impairment Loss	-			
Interest on Borrowings	-		-	
Preliminary Expenditure Amortized	-		-	
Expenditure Amortized	-		-	
Interest on Deposits & Dividend	-		-	
Miscellaneous Income - OTS	-		-	
Deffered Tax	-		7.64	
Prior period Income written off	-		-	
Profit on Sale of Fixed Assets			-	
Loss on Sale of Fixed Assets			-	
		4.80		13.89
Operating Profit Before Working Capital Changes		**24.00**		**(34.25)**
Adjustment for :				
Increase /(Decrease) in other Current Liabilities	(28.33)		(122.46)	
Increase /(Decrease) in Short Term Borrowings	443.00		171.33	
Increase /(Decrease) in Trade Payables	229.88		(2.23)	
Increase /(Decrease) in Long Term Borrowings	(62.00)		(24.43)	
Decrease/(Increase) in other Current Assets	(56.39)			
Decrease/(Increase) in other Non Current Assets	8.50			
Decrease/(Increase) in Capital Work in Progress	(423.34)			
Decrease/(Increase) in Short term Loans and Advances	(82.46)		4.34	
Decrease/(Increase) in Trade Receivables	-		11.10	
		28.85		37.64
Cash Generated From Operations		**52.85**		**3.39**
Adjustment for:				
Prior Period Adjustments	-		-	
Taxes Paid	-		-	
		-		-
NET CASH FROM OPERATING ACTIVITIES - (A)		**52.85**		**3.39**
B. CASH FLOW FROM INVESTING ACTIVITIES:				
Purchase of Fixed Assets	(4.40)		-	
Proceeds from sales of Fixed Assets	-		-	
Proceeds of Long term Investments	-		-	
Interest & Dividend Received	-		-	
NET CASH USED IN INVESTING ACTIVITIES - (B)		**(4.40)**		-
C. CASH FLOW FROM FINANCING ACTIVITIES:				
Borrowings				
a) Term Loans			-	
b) Working Capital Loans			-	
c) Compromise Offer (OTS) difference	-		-	

Interest paid on borrowings		
a) Term Loans	-	
b) Working Capital Loans	-	-
c) Prior Period Income written off	-	-
Unsecured Loans	-	
NET CASH USED IN FINANCING ACTIVITIES - (C)	-	-
Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	**48.45**	**3.39**
Cash and Cash Equivalents at the beginning of the year	**4.34**	**0.95**
Cash and Cash Equivalents at the end of the year	**52.79**	**4.34**

As per our report of even date
For Laxminiwas & Co
Chartered Accountants
Firm's Registration No: 011168S

Vijay Singh
Partner
M. No: 221671

For and on Behalf of Directors
DR. N.R.K. BIO-TECH PRIVATE LIMITED
CIN: U45100TG2014PTC094950

Soham Modi
(Director)
DIN: 00522546

B Anand Kumar
(Director)
DIN: 07739186

Company Secretary
ACS:

Place : Hyderabad
Date :

Place : Hyderabad
Date :

DR. NRK BIOTECH PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS

Note 3 Share capital @

Particulars	As at 31 March, 2022 Number of shares	As at 31 March, 2022 Amount ₹ In Lakhs	As at 31 March, 2021 Number of shares	As at 31 March, 2021 Amount ₹ In Lakhs
AUTHORISED SHARE CAPITAL				
EQUITY SHARE CAPITAL				
Equity shares of Rs.10/- each with voting rights	5,00,000	50.00	5,00,000	50.00
PREFERENCE SHARE CAPITAL				
preference shres of Rs.10/- each	20,00,000	200.00	20,00,000	200.00
TOTAL	25,00,000	250.00	25,00,000	250.00
ISSUED ,SUBSCRIBED & PAID UP CAPITAL :				
EQUITY SHARE CAPITAL				
Equity shares of Rs.10/- each with voting rights	2,50,000	25.00	2,50,000	25.00
PREFERENCE SHARE CAPITAL				
Preference shres of Rs.10/- each	16,78,800	167.88	16,78,800	167.88
TOTAL	19,28,800	192.88	19,28,800	192.88

Notes

(a) Equity Share Capital

(i) Reconciliation of equity shares

Particulars	As at 31 March, 2022 No. of Shares	As at 31 March, 2022 ₹ In Lakhs	As at 31 March, 2021 No. of Shares	As at 31 March, 2021 ₹ In Lakhs
Issued, subscribed and paid-up capital				
At the beginning of the year	2,50,000	25.00	2,50,000	25.00
Add : Issued during the year				
At the closing of the year	2,50,000	25.00	2,50,000	25.00

Note:

(ii) Rights, preference and restrictions attached to Equity Shares

The Company has only one class of equity shares having a par value of ₹ 10 each per share. Each holder of equity shares is entitled to one vote per share. The dividend proposed by the Board of Directors is subject to the approval of the Shareholders in the ensuing Annual General Meeting. In the event of liquidation of the Company, the holders of equity shares will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts if any. The distribution will be in proportion to number of equity shares held by the shareholders.

(iii) Details of Shareholders holding more than 5% equity shares in the Company

Name of the Shareholder	As at 31 March, 2022 Number of shares held	As at 31 March, 2022 % holding in that class of shares	As at 31 March, 2021 Number of shares held	As at 31 March, 2021 % holding in that class of shares
Naga Goverdhan Kumar J	-	-	1,25,000	50.00%
V. Ramesh Kumar Raju	-	-	1,25,000	50.00%
Modi Properties Pvt. Ltd.	46,875	18.75%	-	-
JVRX Asset Management Pvt. Ltd.	15,625	6.25%	-	-
N Kiran Kumar	31,250	12.50%	-	-
N Krishna Veni	31,250	12.50%	-	-
K Venkata Narsimha Murthy	31,250	12.50%	-	-
K Vijay Bhaskar	31,250	12.50%	-	-
B Anand Kumar	31,250	12.50%	-	-
K Venkata Nagabhushnam	31,250	12.50%	-	-
TOTAL	**2,50,000**	**100.00%**	**2,50,000**	**100.00%**

Biotech Private Ltd. HYDERABAD

(iv) Shares held by promoters at the end of the year

Promoter Name	As at 31 March, 2022 Number of shares held	% holding in that class of shares	As at 31 March, 2021 Number of shares held	% holding in that class of shares
Naga Goverdhan Kumar J	-	-	1,25,000	50%
V. Ramesh Kumar Raju	-	-	1,25,000	50%
Modi Properties Pvt. Ltd.	46,875	19%	-	-
JVRX Asset Management Pvt. Ltd.	15,625	6%	-	-
N Kiran Kumar	31,250	13%	-	-
N Krishna Veni	31,250	13%	-	-
K Venkata Narsimha Murthy	31,250	13%	-	-
K Vijay Bhaskar	31,250	13%	-	-
B Anand Kumar	31,250	13%	-	-
K Venkata Nagabhushnam	31,250	13%	-	-
TOTAL	**2,50,000**	**100%**	**2,50,000**	**100%**

(b) Preference Share Capital

(i) Reconciliation of preference shares

Particulars	As at 31 March, 2022 Number of shares held	% holding in that class of shares	As at 31 March, 2021 Number of shares held	% holding in that class of shares
Issued, subscribed and paid-up capital				
At the beginning of the year	19,28,800	193	19,28,800	193
Add : Issued during the year				
At the closing of the year	19,28,800	193	19,28,800	193

Note

(ii) Rights, preference and restrictions attached to Preference Shares

Preference shares shall have priority over the equity shares in respect of payment of dividend and repayment of capital. On liquidation preference shares shall not participate in surplus assets and profits. The payment of dividend is on non-cumulative basis. The preference shares are non-participative and redeemable within a period of 20 years from the date of allotment.

Details of shares held by each preference shareholder holding more than 5% shares:

Class of shares / Name of shareholder

Particulars Preference share holder	As at 31 March, 2022 Number of shares held	% holding in that class of shares	As at 31 March, 2021 Number of shares held	% holding in that class of shares
Naga Goverdhan Kumar J	-	-	1,25,000	7.45%
V. Ramesh Kumar Raju	-	-	1,25,000	7.45%
Dorjee Tsering	-	-	4,76,000	28.35%
Yeshi Dema Thongdok	-	-	4,50,000	26.80%
Kezang Dorjee Thongdok	-	-	5,02,800	29.95%
B Anand Kumar	2,09,850	12.50%	-	-
JVRX Asset Management Pvt. Ltd.	1,04,925	6.25%	-	-
N Kiran Kumar	2,09,850	12.50%	-	-
N Krishna Veni	2,09,850	12.50%	-	-
K Venkata Narsimha Murthy	2,09,850	12.50%	-	-
K Venkata Nagabhushnam	2,09,850	12.50%	-	-
K Vijay Bhaskar	2,09,850	12.50%	-	-
Modi Properties Pvt. Ltd.	3,14,775	18.75%	-	-
TOTAL	**16,78,800**	**100.00%**	**16,78,800**	**100.00%**

(iv) Shares held by promoters at the end of the year

Particulars	As at 31 March, 2022		As at 31 March, 2021	
Preference share holder	Number of shares held	% holding in that class of	Number of shares held	% holding in that class of
Naga Goverdhan Kumar J	-	-	1,25,000	7.45%
V. Ramesh Kumar Raju	-	-	1,25,000	7.45%
Dorjee Tsering	-	-	4,76,000	28.35%
Yeshi Dema Thongdok	-	-	4,50,000	26.80%
Kezang Dorjee Thongdok	-	-	5,02,800	29.95%
B Anand Kumar	2,09,850	12.50%	-	-
JVRX Asset Management Pvt. Ltd.	1,04,925	6.25%	-	-
N Kiran Kumar	2,09,850	12.50%	-	-
N Krishna Veni	2,09,850	12.50%	-	-
K Venkata Narsimha Murthy	2,09,850	12.50%	-	-
K Venkata Nagabhushnam	2,09,850	12.50%	-	-
K Vijay Bhaskar	2,09,850	12.50%	-	-
Modi Properties Pvt. Ltd.	3,14,775	18.75%	-	-
TOTAL	**16,78,800**	**100.00%**	**16,78,800**	**100.00%**

Dr NRK Biotech Private Limited
HYDERABAD

Note No.4 : RESERVES AND SURPLUS

Reserves and Surplus	As at 31st March 2022	₹ In Lakhs As at 31st March 2021
a. Securities Premium Account		
Opening Balance	80.50	80.50
Add : Securities premium credited on Share issue	-	-
Less : Premium Utilised for various reasons	-	-
Premium on Redemption of Debentures	-	-
For Issuing Bonus Shares	-	-
Closing Balance	**80.50**	**80.50**
b. Surplus		
Opening balance	(263.61)	(215.47)
(+) Net Profit/(Net Loss) For the current year	19.20	(48.14)
(+) Transfer from Reserves	-	-
(-) Proposed Dividends	-	-
(-) Interim Dividends	-	-
(-) Transfer to Reserves	-	-
Closing Balance	**(244.42)**	**(263.61)**
Total	**(163.92)**	**(183.11)**

Dr NRK Biotech Private Limited
HYDERABAD

Note No 5: Long Term Borrowings	As at 31st March 2022 ₹ In Lakhs Non-Current	As at 31st March 2021 ₹ In Lakhs Non-Current
A) Secured Loans		
From Bank (Refer Note (i)		
Term Loan	32.43	94.17
B) Unsecured Loans		
(Refer Note (ii))	-	-
TOTAL	32.43	94.17

Note(i)

Secured Loans	As at 31st March 2022 ₹ In Lakhs	As at 31st March 2021 ₹ In Lakhs
(a) Bonds/debentures	-	-
(b) Term loans		
from banks	32.43	94.17
from other parties	-	-
(c) Deferred payment liabilities	-	-
(d) Deposits	-	-
(e) Loans and advances from related parties	-	-
(f) Long term maturities of finance lease obligations	-	-
(g) Other loans and advances (specify nature)	-	-
	32.43	94.17
In case of continuing default as on the balance sheet date in repayment of loans and interest with respect to (b) (e) & (g)		
1. Period of default	-	-
2. Amount	-	-
Total	**32.43**	**94.17**

Note (ii)

Unsecured Loans	As at 31st March 2022 ₹ In Lakhs	As at 31st March 2021 ₹ In Lakhs
(b) Term loans		
From Directors	-	-
from other parties	-	-
(c) Deferred payment liabilities	-	-
(d) Deposits	-	-
(e) Loans and advances from related parties	-	-
(f) Long term maturities of finance lease obligations	-	-
(g) Other loans and advances	-	-
	-	-
In case of continuing default as on the balance sheet date in repayment of loans and interest with respect to (b) (e) & (g)		
1. Period of default	-	-
2. Amount	-	-
	-	-
Total	-	-

Note No.6: SHORT TERM BORROWINGS

Short Term Borrowings	As at 31st March 2022 ₹ In Lakhs	As at 31st March 2021 ₹ In Lakhs
Secured		
(a) Loans repayable on demand		
From Banks	-	200.42
From Other parties		
(b) Loans and advances from related parties	-	-
(c) Deposits	-	-
(d) Other loans and advances	-	-
	-	200.42
In case of continuing default as on the balance sheet date in repayment of loans and interest with respect to (a) (b) & (d)		
1. Period of default	-	-
2. Amount	-	-
Unsecured		
(a) Loans repayable on demand	-	-
(b) Loans and advances from related parties	347.01	168.25
(c) Deposits	-	-
(d) Other loans and advances	464.64	-
	811.65	168.25
In case of continuing default as on the balance sheet date in repayment of l	-	-
1. Period of default		-
2. Amount		-
Total	811.65	368.67

Dr NRK Biotech Private Limited * HYDERABAD

Note No.7: TRADE PAYABLES

Trade Payables	As at 31st March 2022 ₹ In Lakhs	As at 31st March 2021 ₹ In Lakhs
(a) Due payable to Micro Small and Medium Enterprises	-	-
(b) Dues payable to Other Than Micro Small and Medium Enterprises	229.88	-
Total	229.88	-

Note:

The information has been given in respect of such vendors to the extent they could be identified as Micro and

Small enterprises on the basis of the informatioin available with the company on records

Trade payable ageing schedule for the year ended 31.3.2022

₹ In Lakhs

Particulars	Not Due	Outstanding for following periods from due date of payment				
		Less Than 1 year	1-2 Years	2-3 Years	More than 3 years	Total
(i) Undisputed dues - MSME	-	-	-	-	-	-
(ii) Undisputed dues - Others	-	229.88	-	-	-	229.88
(iii)Disputed dues - Others	-	-	-	-	-	-
(iv)Disputed dues - MSME	-	-	-	-	-	-
Total	-	229.88	-	-	-	229.88

Trade payable ageing schedule for the year ended 31.3.2021

₹ In Lakhs

Particulars	Not Due	Outstanding for following periods from due date of payment				
		Less Than 1 year	1-2 Years	2-3 Years	More than 3 years	Total
(i) Undisputed dues - MSME	-	-	-	-	-	-
(ii) Undisputed dues - Others	-	-	-	-	-	-
(iii)Disputed dues - Others	-	-	-	-	-	-
(iv)Disputed dues - MSME	-	-	-	-	-	-
Total	-	-	-	-	-	-

Note No.8: OTHER CURRENT LIABILITIES

Other Current Liabilities	As at 31st March 2022 ₹ In Lakhs	As at 31st March 2021 ₹ In Lakhs
(a) Current maturities of long-term debt		
(b) Current maturities of finance lease obligations	-	-
(c) Interest accrued but not due on borrowings	-	-
(d) Interest accrued and due on borrowings	-	-
(e) Income received in advance	-	-
(f) Unpaid dividends	-	-
(g) Application money received for allotment of securities and due for refund		
Interest accrued on (g) above	-	-
Number of shares proposed to be issued:	-	-
Amount of premium (if any):	-	-
Terms and conditions of shares proposed to be issued:	-	-
Date by which shares shall be alloted:	-	-
The period overdue from the last date of allotment is : reason being		
(h) Unpaid matured deposits and interest accrued thereon	-	-
(i) Unpaid matured debentures and interest accrued thereon	-	-
(j) Other payables :	-	-
TDS Payable	5.95	-
GST Payable	0.15	-
Others	-	34.74
	-	-
Audit Fee Payable	0.30	-
Total	**6.40**	**34.74**

Dr NRK Biotech Private Limited HYDERABAD

DR. NRK BIOTECH PRIVATE LIMITED

Notes to Financial Statements

₹ In Lakhs

Note: 9 : FIXED ASSETS

	GROSS BLOCK				DEPRECIATION				NET BLOCK	
	As at 1-Apr-21	Additions	Deletions/ adjustments	As at 31-Mar-22	As at 1-Apr-21	For the Year	Deletions/ adjustments	As at 31-Mar-22	As at 31-Mar-22	As at 31-Mar-21
Property, Plant and Equipment										
Land	158.43	-	-	158.43	-	-	-	-	158.43	158.43
Buildings	80.42	-	-	80.42	20.81	4.47	-	25.28	55.14	59.61
Vehicles	-	4.40	-	4.40	-	0.33	-	0.33	4.07	4.07
Sub Total	**238.85**	**4.40**	-	**243.24**	**20.81**	**4.80**	-	**25.61**	**217.63**	**222.10**
Previous Year	238.85	-	-	238.85	14.55	6.26		20.81	224.29	218.03
CAPITAL WORK IN PROGRESS:										
Capital Work In Progress (Building constr	276.22	423.34	-	699.56	-	-	-	-	699.56	256.82
Sub Total	**276.22**	**423.34**	-	**699.56**	-	-		-	**699.56**	**256.82**
TOTAL(A)	**515.06**	**427.74**	-	**942.80**	**20.81**	**4.80**	-	**25.61**	**917.19**	**478.92**

CWIP Ageing for FY 2021-22

₹ In Lakhs

Particulars	As on 31.03.2022 Amount in CWIP for a period of				
	Less Than 1 year	1-2 Years	2-3 Years	More than 3 Years	Total
Projects in progress	423.34	-	276.22	-	699.56

CWIP Ageing for FY 2020-21

₹ In Lakhs

Particulars	As on 31.03.2021 Amount in CWIP for a period of				
	Less Than 1 year	1-2 Years	2-3 Years	More than 3 Years	Total
Projects in progress	276.22	-	-	-	276.22

Dr. NRK Biotech Private Limited * HYDERABAD

DR. NRK BIOTECH PRIVATE LIMITED

Notes on Financial Statements

Note 10 : NON CURRENT INVESTMENTS	As at 31.03.2022 ₹ In Lakhs		As at 31.03.2021 ₹ In Lakhs	
b.Investments in Equity Instruments	-	-	-	-
c.Investments in preference shares	-	-	-	-
d.Investments in Government or trust securities	-	-	-	-
e.Investments in debentures or bonds	-	-	-	-
f.Investments in Mutual Funds	-	-	-	-
g.Investments in Partnership Firms	-	-	-	-
h.Other non-current Investments- Share	-	-	-	-
Application Money	-	-	-	-
TOTAL	-	-	-	-

Note 11 : DEFFERED TAX	As at 31.03.2022 ₹ In Lakhs	As at 31.03.2021 ₹ In Lakhs
Deffered Tax	36.41	0.26
TOTAL	36.41	0.26

Note 12 : OTHER NON CURRENT ASSETS	As at 31.03.2022 ₹ In Lakhs		As at 31.03.2021 ₹ In Lakhs	
receivables on deferred credit terms)				
Secured, considered good	-		8.50	
Unsecured, considered good	-		-	
Doubtful	-		-	
Less: Provision for doubtful debts	-	-	-	8.50
	-	-	-	8.50
b. Others (specify nature)				
Secured, considered good	-		-	
Unsecured, considered good	-		-	
Doubtful	-		-	
Less: Provision for doubtful debts	-	-	-	-
	-	-	-	-
c. Debts due by related parties (refer note 2)				
Secured, considered good	-		-	
Unsecured, considered good	-		-	
Doubtful	-		-	
Less: Provision for doubtful debts	-	-	-	-
	-	-	-	-
TOTAL		-		8.50

Note 13 : CASH AND CASH EQUIVALENTS	As at 31.03.2022 ₹ In Lakhs		As at 31.03.2021 ₹ In Lakhs	
a. Balances with banks				
Bank Balance	12.39		0.25	
	-	12.39	-	0.25
b. Bank deposits with more than 12 months maturity				
	-		-	
	-	-	-	-
c. Cheques, drafts on hand	-	-	-	-
d. Cash on hand*	4.25	4.25	4.09	4.09
e. Others (specify nature)	-		-	-
TOTAL		16.6[illegible]		4.34

NRK Biotech Private Limited HYDERABAD

Note 14 : SHORT TERM LOANS AND ADVANCES	As at 31.03.2022 ₹ In Lakhs		As at 31.03.2021 ₹ In Lakhs	
Unsecured, considered good	15.68		-	
Doubtful	-		-	
Less: Provision for doubtful loans and advances	-		-	-
	-	15.68	-	-
b. Other loans and advances (specify nature)				
Secured, considered good			-	
Unsecured, considered good	66.78		-	
Doubtful	-		-	
Less: Provision for	-		-	-
	-	66.78	-	-
TOTAL		82.46		-

Note 15 : OTHER CURRENT ASSETS	As at 31.03.2022 ₹ In Lakhs	As at 31.03.2021 ₹ In Lakhs
Deposits	-	-
GST Input	56.61	-
TOTAL	**56.61**	-

DR. NRK BIOTECH PRIVATE LIMITED

Notes on Financial Statements

Note No.16: REVENUE FROM OPERATIONS	For the period ended 31.03.2022 ₹ In Lakhs	For the period ended 31.03.2021 ₹ In Lakhs
Sale of Products	-	-
Sale of Services	-	-
Total	-	-

Note No.17: OTHER INCOME	For the period ended 31.03.2022 ₹ In Lakhs	For the period ended 31.03.2021 ₹ In Lakhs
Interest Income (in case of a company other than a finance company)	-	-
Dividend	-	0.009
Total	-	**0.009**

Note No 18 : CONSUMPTION	For the Year ended 31 March 2022 ₹ in lakhs	For the Year ended 31 March 2021 ₹ in lakhs
Opening stock	-	-
Add: Purchases	423.34	-
Less: Closing stock including Material in Transit	-	-
Less: Amount transferred to CWIP	423.34	-
Total	-	-

Note No.19: EMPLOYEES BENEFIT EXPENSES	For the year ended 31 March 2022 ₹ In Lakhs	For the year ended 31 March 2021 ₹ In Lakhs
Salaries, Remuneration and Wages	1.56	-
Total	**1.56**	-

Dr NRK Biotech Private Limited
HYDERABAD

Note No.20: ADMINISTRATION EXPENSES	For the year ended 31 March 2022 ₹ In Lakhs	For the year ended 31 March 2021 ₹ In Lakhs
Audit fee	0.30	0.24
Insurance Premium	-	0.69
Written Off	5.94	8.80
Admin Service Charges	0.20	-
Admin Service Charges 18%	0.57	-
Staff - Comm. & Logestics 18%	1.88	-
Maintenance Charges	0.09	-
ROC Charges	0.03	-
GST Late Fees	0.01	-
Other miscellaneous expenses	0.01	-
Park Maintenance Charges	0.93	-
Total	**9.95**	**9.73**

Note No.21: FINANCE COST	For the year ended 31 March 2022 ₹ In Lakhs	For the year ended 31 March 2021 ₹ In Lakhs
Bank charges	0.04	0.23
Processing Charges	-	1.14
Interest on FTL	-	0.45
Interest on SOD	-	5.83
Interest on Term Loan	-	16.87
Penal Interest on SOD	0.40	-
Penal Interest on Term Loan	0.21	-
	-	-
Total	**0.65**	**24.52**

DR. N.R.K. BIO-TECH PRIVATE LIMITED

NOTES TO FINANCIAL STATEMENTS
For the Period ended 31st March 2022

NOTE 1: SIGNIFICANT ACCOUNTING POLICIES

1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS

(a) Basis of Accounting

The financial statements of **Dr. N.R.K. Bio-Tech Private Limited** have been prepared and presented under the historical cost convention, on the accrual basis of accounting in accordance with the accounting principles Generally Accepted in India (Indian GAAP) and comply with Accounting Standards prescribed in the Companies (Accounting Standards) Rules, 2006 which continue to apply under section 133 of the companies Act. 2013 (the Act) read with Rule 7 of the Companies (Accounts) Rules, 2014.

(b) Use of Estimates

The preparation of financial statements in conformity with Indian GAAP requires judgments, estimates and assumptions to be made that affect the reported amount of assets and liabilities, disclosure of contingent liabilities on the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Difference between the actual results and estimates are recognized in the period in which the results are known/materialized.

(c) Current/ Non-Current Classification

All assets and liabilities have been classified as current or non-current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. Based on the nature of products and the time between acquisition of assets for processing and their realization in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current/non-current classification of assets and liabilities.

1.2 REVENUE / EXPENDITURE RECOGNITION

Expenditure is accounted for on accrual basis and provision is made for all known expenditure and obligations.

1.3 TANGIBLE AND INTANGIBLE ASSETS

Fixed Assets are stated at cost less accumulated depreciation. Gross block of Fixed Assets is stated at cost of acquisition or construction, including all cost attributable to bring the asset to their working condition for their intended use.

Pursuant to the requirements under Schedule II to the Companies Act, 2013, the Company has identified and determined the cost of each component of an asset separately when the component has

Dr NRK Biotech Private Limited HYDERABAD

a cost which is significant to the total cost of the asset and has useful life that is materially different from that of the remaining asset.

1.4 DEPRECIATION

Depreciation on Fixed Assets is provided on the Straight Line Method (SLM) over the useful life of assets as specified in Schedule II to the Companies Act, 2013 and is charged to the statement of profit and loss.

1.5 INVENTORIES

Inventories shall be valued at cost or net realizable value, whichever is lower. Cost is determined on weighted average basis.

1.6 TAXATION

Tax expenses comprises of current tax (i.e, amount of tax for the period determined in accordance with the income Tax Act., 1961) and deferred tax charge or credit (reflecting the tax effects of timing differences between accounting income and taxable income for the period).

(a) Current Tax:

The Provision for taxation is based on assessable profits of the company as determined under the Income Tax Act, 1961.

(b) Deferred Tax:

The company is providing and recognizing deferred tax on timing difference between taxable income and accounting income subject to consideration of prudence.

1.8 EMPLOYEE BENEFITS

(a) Defined Contribution Plan:

Contribution as per the Employee's Provident Fund and Miscellaneous Provisions Act,1952 towards Provident Fund and Family Pension Fund are provided for and payments in respect thereof are made to the relevant authorities on actual basis.

(b) Defined Benefit Plan:

Gratuity:
In accordance with applicable Indian Laws, the company provides gratuity for the eligible employees (Completed 5 years of Service / employees transferred from the companies working under the same management without break in service). The gratuity provides lump sum payment at retirement or termination of employment, an amount based on the respective employee's last drawn salary and the years of employment with the Company. Liability in respect of Gratuity is recognized and debited to P&L Account.

Dr. NRK Biotech Private Limited HYDERABAD

Leave Encashment:
In accordance with applicable Indian Laws, the Company provides Encashment of Leave covering all employees. Liability with regard to Leave Encashment is recognized and debited to P&L Account.

1.9 BORROWING COST

Borrowing costs, which are directly attributable to the acquisition/construction of fixed assets, till the time such assets are ready for intended use, are capitalized as part of the costs of such assets. Other Borrowing costs are recognized as expenses in the year in which they are incurred.

1.10 IMPAIRMENT OF ASSETS

The Asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. An impairment loss is charged to the Profit and Loss Statement in the year in which an asset is identified as impaired. The Impairment loss recognized in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

1.11 PROVISIONS AND CONTINGENCIES

The company creates a provision when there exists a present obligation as a result of past event that probably requires an outflow of resources and a reliable estimate can be made of the amount of the obligation. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation or a present obligation in respect of which likelihood of outflow of resources. When there is a possible obligation or a present obligation in respect of which likelihood of outflow of resources is remote, no provision or disclosure is made.

1.12 EARNING PER SHARE

The Basic earnings per share ('EPS') is computed by dividing the net profit after tax for the period attributable to equity shareholders (after deducting preference dividends and attributable taxes) by weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit after tax for the period attributable to equity shareholders and the weighted average number of shares outstanding during the year after adjusted for the effects of all dilutive potential equity shares. The dilutive potential equity shares are deemed to be converted as of the beginning of the year, unless they have been issued at a later date.

Dr NRK Biotech Private Limited
HYDERABAD

Note 2: **Notes to Financial Statements**

2.22 EARNING PER SHARE (EPS)

The computation of EPS is set out below:

Particulars	2021-22	2020-21
Earnings		
Net profit / (Loss) after taxes	**19.20**	**(48.14)**
Shares		
Number of Shares at the beginning of the period	2.5	2.5
Add: Issued Shares during the period	Nil	Nil
Total Number of Equity Shares Outstanding during the period	Nil	Nil
Weighted average Number of Shares during the period	Nil	Nil
Earnings per share of par value Rs.10/- Basic & Diluted (Rs.)	**7.68**	**(19.26)**

2.23 RELATED PARTY DISCLOSURES

A. List of Related parties:

I) Directors / Relatives

S No	Name of the Related Party	Nature of Relationship
1	N Kiran Kumar	Key Management Personnel
2	N Krishna Veni	Key Management Personnel
3	K Venkata Narsimha Murthy	Key Management Personnel
4	K Vijay Bhaskar	Key Management Personnel
5	B Anand Kumar	Director
6	K Venkata Nagabhushnam	Key Management Personnel

II) Companies in which Director's having interest with whom transactions have taken place

S No	Name of the Related Party
1	Modi Properties Pvt. Ltd.
2.	JVRX Asset Management Pvt. Ltd.
3	Modi Constructions & Realtors LLP

Dr NRK Biotech Private Limited ★ HYDERABAD

B. Transactions / Balance Outstanding with related parties

Transactions / Out Standing Balances	Expenditure Incurred	Income Received	Balance at the beginning of the year	Accepted/ Received	Given/ Repaid	Balance at the end of the year
Expenditure			-	-	-	-
Nil	-	-	-	-	-	-
Income						
Nil	-		-	-	-	-
Inter corporate deposits given/received						
ICD's from Modi Properties Pvt Ltd (Company under the same Management)	-	-	-	198.20	-	198.20
B Anand Kumar	-	-	-	148.80	-	148.80
K Venkata Nagabhushnam	-	-	-	98.80	-	98.80
N Kiran Kumar	-	-	-	93.80	-	93.80
N Krishna Veni	-	-	-	23.80	-	23.80
K Vijay Bhaskar	-	-	-	108.80	-	108.80
K Venkata Narsimha Murthy	-	-	-	48.80	-	48.80
JVRX Asset Management Pvt. Ltd.	-	-	-	90.62	-	90.62
Summary at the year end.	-	-	-	**811.65**	-	**811.65**
Unsecured Loans Payable	-		-	-	-	613.44
ICD's Payable	-		-	-	-	198.20
ICD's Receivable	-		-	-	-	-

2.24 No asset is impaired during the year as the assets are having recoverable value which is more than the carrying amount.

2.25 DEFERRED TAX

Rs in Lakhs

Particulars	Deferred Tax (Liability)/ Asset as at 01.04.2021	Current year charge (Credit) / Debit	Deferred Tax (Liability) Asset as at 31.03.2022
Deferred Tax Asset/ (Liability)	0.26	36.15	36.41

The Company is providing and recognizing deferred tax on timing differences between taxable income and accounting income subject to consideration of prudence.

Dr NRK Biotech Private Limited HYDERABAD

2.26 RETIREMENT BENEFITS

Contribution to PF / ESI is charged to Revenue. Management has not obtained actuarial valuation for gratuity and leave encashment as there is no employees on rolls. However the provision is made for Gratuity and Leave encashment on accrued basis.

2.27 Letters have been written for confirmation of debit and credit balances pertaining to debtors and creditors, and to the shareholders for confirmation of investments in equity of the company, the reply from the parties and investors is awaited.

2.28 Previous year figures have been regrouped wherever necessary to confirm to current year's grouping/ classification.

2.29 Statutory Auditor's remuneration

₹ in lakhs

Sl. No	Description	Year 2021-22	Year 2020-21
1	Statutory Audit	0.30	0.24
2	Tax Audit	-	-
3	Certification fee / Taxation matter	-	-

2.30 KEY RATIOS

Definitions:

(a) Current Assets = Total current assets as per balance sheet
(b) Current Liabilities = Total Current Liabilities as per Balance sheet
(c) Debt = Long term and short term borrowings as per Note 3 and Note 6 respectively
(d) Equity/Shareholder Equity = Total Equity as per balance sheet
(e) Capital Employed = Total Assets - Current Liabilities

S.no	Particulars	Numerator	Denominator	31.03.2022	31.03.2021	Variance	Reason for Variance more than 25%
1	Current Ratio (in times)	Current assets	Current liabilities	0.149	0.011	0.85%	-
2	Debt- Equity Ratio (in times)	Debt	Equity	4.376	2.40	3.38%	-
3	Return on equity (in%)	Profit After Tax	Shareholder equity	-2.359%	-4.93%	-1.36%	-
4	Return on Capital Employed	Earnings before Interest and Taxes	Capital Employed	-2.359%	-4.15%	-1.36%	-

2.31 Other Statutory Information

(i) The Company does not have any Benami property where any proceeding has been initiated or pending against the Group for holding any Benami property.

(ii) The quarterly returns or statements of current assets filed by the company with banks or financial institutions are in agreement with the books of accounts.

(iii) The Company has not been declared willful defaulter by any bank or financial institution or government or any government authority.

(iv) The Company does not have any transactions with companies struck off.

(v) The Company does not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period.

(vi) The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies) including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

Dr NRK Biotech Private Limited
HYDERABAD

(a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or
(b) Provide any guarantee security or the like to or on behalf of the Ultimate Beneficiaries.

(vii) The Company has not received any fund from any person(s) or entity(ies) including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Group shall:

(a) Directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or
(b) Provide any guarantee security or the like on behalf of the Ultimate Beneficiaries.

(viii) The Company has not entered into any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act 1961 (such as search or survey or any other relevant provisions of the Income Tax Act 1961)

(xi) The Company has not traded or invested in Crypto currency or Virtual Currency during the financial year.

As per our report of even date

For Laxminiwas & Co
Firm Registration No: 011168S
Chartered Accountants

Vijay Singh
Partner
M. No. 221671

Place: Hyderabad
Date:

For and on behalf of the Board
Dr. N.R.K. Bio-Tech Private Limited
CIN: U45100TG2004PTC044950

Soham Modi	**B Anand Kumar**
Director	**Director**
DIN: 00522546	**DIN: 07739186**